串叶松香草多倍体植株的组织培养

植物名称:串叶松香草(Silphium perfolia—tum)。材料类别:幼苗的胚轴。培养条件:将种子用水浸泡12小时后移至500ppm的秋水仙素溶液处理12小时,然后种置于砂基培养基内,室内培养。待其长出幼苗时,取其膨大的胚轴部分接种于培养基上,置于25±0.5℃的培     

串叶松香草

串叶松香草(Silphiam perfoliatum)是原产加拿大和美国南部、西部的菊科草本植物。因它的根带有松香味,茎上部叶片的基部相连成杯状,茎杆从中贯串而出,而得名为串叶松香草。1979年引入我国。 (一)植物学特征多年生草本。株高2—3米。根为直根系。茎直立,四棱形,光滑无毛,上部分枝。叶对生,卵形,长15—20厘米,宽10—20厘米,先端急尖,下部叶基部渐狭成柄,边缘具齿,两面具糙柔毛。头状花序,在茎顶成伞房状,直径5—7.5厘米;总苞苞片数层,覆瓦状排列;舌状花黄色,2—3轮,舌片先端具3齿,能育;管状花黄色,两性,不育。瘦果,扁而具翅,呈倒卵形;冠毛芒状。 (二)生长习性在适宜条件下,充实饱满的种子播种后6—10天幼苗出土,两片子叶呈椭圆形。第一年长势缓慢,只进行营养生长,形成基生叶丛,一般12—18片,水肥条件充分时可达30片叶。不抽茎开花。第二年春季萌芽后,长势明显增强。华北地区,6月中旬     

串叶松香草的核型研究

串叶松香草Silphiura perfoliatum L.系菊科(Compositae)松香草属(SilphiumL.)多年生宿根草本植物,原产北美洲。1979年由中国科学院植物研究所北京植物园首次从朝鲜引进我国,1980年引种我所栽培,通过几年的试验观察表明:串叶松香草是一种高产、质优、适应性强的饲料作物,近年来,我省广泛发展和应用。据文献报     

兰香草的组织培养与快速繁殖

1植物名称 兰香草[Caryopteris incana（Thunb．）Miq．]。 2材料类别 茎段。 3培养条件 以MS为基本培养基。芽诱导培养基：（1）MS＋6-BA0．5mg·L^-1（单位下同）＋IBA0．2;（2）MS＋6-BA1．0＋IBA0．2。     

灵香草的组织培养与快速繁殖

1植物名称灵香草（Lysimachia foenum-graecumHance）。2材料类别顶芽。3培养条件芽的生长及分化培养基：（1）MS;（2）MS＋6-BA 1.0 mg·L-（-1）（单位下同）＋NAA 0.5;（3）MS＋6-BA 2.0＋NAA 0.5;（4）MS＋6-BA 3.0＋NAA 1.0;（5）1/2MS;（6）1/2MS＋6-BA 1.0＋NAA 0.5;（7）1/2MS＋6-BA 2.0＋NAA 0.5;（8）1/2MS＋6-BA 3.0＋NAA 1.0。丛生芽诱导培养基：（9）MS＋6-BA 0.5＋NAA 0.2＋1g·L-（-1）活性碳;（10）MS＋6-BA 1.0＋NAA 0.2＋1 g·L-（-1）活性碳;（11）MS＋6-BA 2.0＋NAA 1.0＋1 g·L-（-1）活性碳;     

串叶松香草的药用成分分析

本文对串叶松香草的药用成分作了定性分析,并对松香草中的核黄素和单宁作了较深入的探讨,结合用该草作的抗疲劳试验和各地的饲喂实践,可以看出,串叶松香草是一种既有高营养价值,又有多种药物疗效的优质饲草。     

白木香组织培养及快速繁殖

白木香腋芽外植体在含０．０５ｍｇ／ＬＢＡＰ的ＭＳ基本培养基上增殖系数为４．９３。采用间接法诱导芽生根,生根率达９４．４％。白木香试管苗移栽成活率为９３．８％。     

海巴戟的组织培养及快速繁殖

1植物名称海巴戟（MorindacitrifoliaL．）。 2材料类别从美国加里福尼亚叶启恩先生处得到大溪种海巴戟种子,擦伤外壳后播种于砂盆中,可比未用粗砂擦伤外壳的提前4个月发芽（后者为6个月）,植株长出2片完全叶时,取茎段和顶芽作实验材料。     

Curcuminoids as inhibitors of thioredoxin reductase: A receptor based pharmacophore study with distance mapping of the active site

Curcumin is the yellow pigment of turmeric that interacts irreversibly forming an adduct with thioredoxin reductase (TrxR), an enzyme responsible for redox control of cell and defence against oxidative stress. Docking at both the active sites of TrxR was performed to compare the potency of three naturally occurring curcuminoids, namely curcumin, demethoxy curcumin and bis-demethoxy curcumin. Results show that active sites of TrxR occur at the junction of E and F chains. Volume and area of both cavities is predicted. It has been concluded by distance mapping of the most active conformations that Se atom of catalytic residue SeCYS498, is at a distance of 3.56 from C13 of demethoxy curcumin at the E chain active site, whereas C13 carbon atom forms adduct with Se atom of SeCys 498. We report that at least one methoxy group in curcuminoids is necessary for interation with catalytic residues of thioredoxin. Pharmacophore of both active sites of the TrxR receptor for curcumin and demethoxy curcumin molecules has been drawn and proposed for design and synthesis of most probable potent antiproliferative synthetic drugs.     

Synthesis and antimicrobial studies of hydrazone derivatives of 4-[3-(2,4-difluorophenyl)-4-formyl-1H-pyrazol-1-yl]benzoic acid and 4-[3-(3,4-difluorophenyl)-4-formyl-1H-pyrazol-1-yl]benzoic acid

Microbial resistance to antibiotics is an unresolved global concern, which needs urgent and coordinated action. One of the guidelines of the Centers for Disease Control and Preventions (CDC) to combat antibiotic resistance is the development of new antibiotics to treat drug-resistant bacteria. In our effort to find new antibiotics, we report the synthesis and antimicrobial studies of 30 new pyrazole derivatives. These novel molecules have been synthesized by using readily available starting materials and benign reaction conditions. Some of these molecules have shown activity with MIC values as low as 0.78?µg/mL against four bacterial strains; Staphylococcus aureus, methicillin-resistant S. aureus, Bacillus subtilis, and Acinetobacter baumannii. Furthermore, active molecules are non-toxic to mammalian cell line.

     

Novel compounds with potent CDK9 inhibitory activity for the treatment of myeloma

Cyclin-dependent kinases (CDKs) and Polo-like kinases (PLKs) play key role in the regulation of the cell cycle. The aim of our study was originally the further development of our recently discovered polo-like kinase 1 (PLK1) inhibitors. A series of new 2,4-disubstituted pyrimidine derivatives were synthesized around the original hit, but their PLK1 inhibitory activity was very poor. However the novel compounds showed nanomolar CDK9 inhibitory activity and very good antiproliferative effect on multiple myeloma cell lines (RPMI-8226).